Table 1. Shigella vaccines currently in clinical development*.
| Target | Serotype | Technology | Translational | Phase 1 | Phase 2a |
|---|---|---|---|---|---|
| Single Serotype | S. flexneri 2a | Bioconjugate | Flexyn2a a (LMTB) NCT02388009 | ||
| Synthetic Conjugate | Sf2a-TT15 (IP) NCT02797236 | Sf2a-TT15 (IP) NCT04602975 | |||
| Invasin Complex | InvaplexAR (WRAIR) NCT02445963 | ||||
| InvaplexAR-Detox (WRAIR) NCTO3869333 | |||||
| S. sonnei | GMMA | 1790GAHB a (GSK) NCT02017899 NCT02034500 NCT03089879 | 1790GAHB a (GSK) NCT02676895 | ||
| Live-Attenuated Oral | WRSs2 (WRAIR/NIAID) NCT01336699 | ||||
| Multiple Serotypes | S. sonnei and S. flexneri 2a, 3a, 6 | Bioconjugate | Shigella4V (LMTB) NCT04056117 | Shigella4V (LMTB) NCT04056117 | |
| S. sonnei and S. flexneri 1b, 2a, 3a | GMMA | altSonflex1-2−3 (GSK) NCT05073003 | |||
| Multi-Pathogen | S. flexneri 2a, ETEC | Live-Attenuated Oral | CVD1208S-122 (UMD) | ||
| NCT04634513 | |||||
| Live-Attenuated Oral | ShigETEC (Eveliqure) Harutyunyan et al. (2020) |
a
Single serotype candidate vaccine development terminated in favor of multi-serotype candidate vaccine
*
Trial status: Not yet recruiting/recruiting; Active/Ongoing; Completed
Product Developers
Eveliqure—Eveliqure Biotechnologies GmbH (Vienna, AT); GSK—GSK Vaccines Institute for Global Health (Siena, IT); IP—Institut Pasteur (Paris, FR); LMTB—LimmaTech Biotechnology (Zurich, CH); NIAID—National Institutes of Allergy and Infectious Diseases (Bethesda, MD, USA); UMD—University of Maryland (Baltimore, MD, USA); WRAIR—Walter Reed Army Institute of Research (Silver Spring, MD, USA)